Nykode Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Nykode Therapeutics has a total shareholder equity of $142.6M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $168.4M and $25.8M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$124.62m |
| Equity | US$142.64m |
| Total liabilities | US$25.77m |
| Total assets | US$168.41m |
Recent financial health updates
We're Keeping An Eye On Nykode Therapeutics' (OB:NYKD) Cash Burn Rate
Aug 05
We Think Nykode Therapeutics (OB:NYKD) Can Easily Afford To Drive Business Growth
Aug 20Nykode Therapeutics (OB:NYKD) Is In A Strong Position To Grow Its Business
Apr 06Recent updates
We're Keeping An Eye On Nykode Therapeutics' (OB:NYKD) Cash Burn Rate
Aug 05Earnings Update: Nykode Therapeutics AS (OB:NYKD) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts
Mar 02Risks To Shareholder Returns Are Elevated At These Prices For Nykode Therapeutics AS (OB:NYKD)
Jan 22We Think Nykode Therapeutics (OB:NYKD) Can Easily Afford To Drive Business Growth
Aug 20Nykode Therapeutics (OB:NYKD) Is In A Strong Position To Grow Its Business
Apr 06Financial Position Analysis
Short Term Liabilities: NYKD's short term assets ($128.7M) exceed its short term liabilities ($16.2M).
Long Term Liabilities: NYKD's short term assets ($128.7M) exceed its long term liabilities ($9.6M).
Debt to Equity History and Analysis
Debt Level: NYKD is debt free.
Reducing Debt: NYKD has not had any debt for past 5 years.
Debt Coverage: NYKD has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: NYKD has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 08:44 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Nykode Therapeutics AS is covered by 4 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Viktor Sundberg | ABG Sundal Collier Sponsored |
| Geir Holom | DNB Markets |
| Patrick Trucchio | H.C. Wainwright & Co. |